(Q38286198)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

review article

1 reference

title

Pharmacological reactivation of p53 as a strategy to treat cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

J Zawacka-Pankau

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

1 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

Journal of Internal Medicine

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

248-259

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

Blinded by the Light: The Growing Complexity of p53

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

The consensus coding sequences of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Mutational heterogeneity in cancer and the search for new cancer-associated genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Modeling the therapeutic efficacy of p53 restoration in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Restoration of p53 function leads to tumour regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Temporal dissection of p53 function in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Mutant p53 proteins: between loss and gain of function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Mutant p53 in cancer: new functions and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

p53 and the Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Assessing TP53 status in human tumours to evaluate clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Mutant p53: an oncogenic transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Stage-specific sensitivity to p53 restoration during lung cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Selective activation of p53-mediated tumour suppression in high-grade tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Drug discovery and mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Biochemical characterization of different conformational states of the Sf9 cell-purified p53His175 mutant protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Small molecule induced reactivation of mutant p53 in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Allele-specific p53 mutant reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

The missing zinc: p53 misfolding and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

The substitutions G245C and G245D in the Zn(2+)-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Non-genotoxic anti-neoplastic effects of ellipticine derivative NSC176327 in p53-deficient human colon carcinoma cells involve stimulation of p73

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

MDM2, MDMX and p53 in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

MDM2 and MDMX in cancer and development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Identification of inhibitors for MDM2 ubiquitin ligase activity from natural product extracts by a novel high-throughput electrochemiluminescent screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

MDM4 is a key therapeutic target in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Identification and characterization of the first small molecule inhibitor of MDMX

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

A small-molecule inhibitor of MDMX activates p53 and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Regulation of HDM2 activity by the ribosomal protein L11

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

A targeting modality for destruction of RNA polymerase I that possesses anticancer activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12336

21 January 2018

Identifiers

DOI

10.1111/JOIM.12336

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25495071%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference